ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

glecirasib

Also written as “JAB-21822”, “JAB-21822 (KRAS G12C inhibitor)” and “Glecirasib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Appendiceal Neoplasms · Pancreatic Neoplasms, led by 4 companies.

Drug pageGlecirasib: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 9, 202412 company-led studies, 8 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Allist Pharmaceuticalsits history only96 open or runningphase 3since May 9, 2024Jul 26, 2021Dec 31, 2026phase 2 · NCT06008288
Abbisko Cayman11 open or runningphase 2since Sep 2, 2025Sep 2, 2025Dec 30, 2028phase 2 · NCT07164170
Jacobio Pharmaceuticalsits history only10 open or runningphase 2since Jul 26, 2021Jul 26, 2021none ahead
Sichuan Biokin Pharmaceuticalits history only11 open or runningphase 2since Sep 14, 2026Sep 14, 2026Dec 2028phase 2 · NCT07827261

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Abbisko Cayman only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2023Named glecirasibINNProposed as its International Nonproprietary Name in WHO's List 129 · before, JAB-21822, JAB 21822
  2. Sep 2, 2025First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07164170 · 86 planned · China

Ahead

  1. Dec 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07164170

TargetBeta

KRAS →read by rule
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

The one study Abbisko Cayman leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07164170Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 30, 202886

How it is read

Names in the registry

  • “JAB-21822”, 10 entries
  • “JAB-21822 (KRAS G12C inhibitor)”, 3 entries
  • “Glecirasib”, 1 entry
  • “JAB 21822”, 1 entry
  • “ABSK043 in combination with Glecirasib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.